MTOR and renal cell carcinoma: To further investigate the anti-proliferation ability, we combined DZ-CIS with mTOR inhibitors everolimus (EVE) or temsirolimus (TEM), which was used to inhibit advanced RCC in case sunitinib and/or sorafenib treatment fails [34].